Editorial Commentary


Is it time for a specific score for venous thromboembolism risk assessment for non-solid tumors?

Ariane Vieira Scarlatelli Macedo, Eduardo Ramacciotti

Abstract

Cancer patients have a high incidence of venous thromboembolism (VTE), VTE recurrence, bleeding and reduced quality of life (1). Thrombosis is the second most common cause of death in cancer patients (2). VTE prophylaxis is not routinely recommended for all outpatients with cancer undergoing chemotherapy.

Download Citation